Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...

IP3/DAG Signaling Pathway

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Novel mass spectral fragmentation of heptafluorobutyryl derivatives of acyl analogues of platelet-activating factor.

Journal of the American Society for Mass Spectrometry·2013

Same author

A new phospholipide-splitting enzyme specific for the ester linkage between the nitrogenous base and the phosphoric acid grouping.

The Journal of biological chemistry·2010

Same author

The phosphorus-containing lipides of the carrot.

The Journal of biological chemistry·2010

Same author

Characterization of an intraperitoneal ovarian cancer xenograft model in nude rats using noninvasive microPET imaging.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2007

Same author

Peri-implant inflammation defined by the implant-abutment interface.

Journal of dental research·2006

Same author

Persistent acute inflammation at the implant-abutment interface.

Journal of dental research·2003

Search research articles

Related Experiment Video

Updated: Jul 20, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Human platelet stimulation by acetyl glyceryl ether phosphorylcholine

L M McManus, D J Hanahan, R N Pinckard

The Journal of Clinical Investigation

|March 1, 1981

Summary

Acetyl glyceryl ether phosphorylcholine (AGEPC) triggers platelet aggregation and serotonin release. Indomethacin and ADP scavengers block irreversible aggregation, while prostacyclin inhibits both aggregation and secretion.

Area of Science:

Biochemistry
Hematology
Pharmacology

Background:

Platelet activation is crucial for hemostasis and thrombosis.
Acetyl glyceryl ether phosphorylcholine (AGEPC) is a lipid mediator involved in platelet responses.
Understanding AGEPC's role requires elucidating its signaling pathways.

Purpose of the Study:

To investigate the effects of Acetyl glyceryl ether phosphorylcholine (AGEPC) on human platelet aggregation and secretion.
To identify the mechanisms underlying AGEPC-induced platelet activation.

Main Methods:

Human platelet-rich plasma was used to study platelet aggregation and [3H]serotonin release.
Dose-dependent responses to AGEPC were measured.
The effects of ADP scavengers, indomethacin, prostacyclin, EDTA, and EGTA were evaluated.

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Related Experiment Videos

Last Updated: Jul 20, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Main Results:

AGEPC induced dose-dependent platelet aggregation and release of [3H]serotonin and platelet factor 4.
Irreversible aggregation was prevented by ADP scavengers or indomethacin, but secretion was unaffected.
Prostacyclin inhibited both AGEPC-induced aggregation and secretion.
EDTA or EGTA inhibited aggregation but not secretion.

Conclusions:

AGEPC activates platelets through pathways involving both aggregation and secretion.
Irreversible aggregation is mediated by ADP-dependent mechanisms.
Secretion is independent of ADP and calcium, suggesting distinct signaling pathways for aggregation and secretion.